Charles River Laboratories International, Inc. (CRL)

Over the past six months, Charles River Laboratories' stock (CRL) has experienced mixed performance, trading essentially flat overall, but with a 29.70% increase between April 7, 2025, and April 2, 2026. Key events impacting the stock include improving DSA demand indicators, Q4 2025 earnings and 2026 guidance, strategic initiatives and headwinds related to animal testing and AI competition, and analyst ratings and price targets. In December 2025, Charles River Laboratories reported improving demand indicators in its Discovery and Safety Assessment (DSA) segment. On February 18, 2026, Charles River Laboratories announced its fourth-quarter and full-year 2025 results and provided 2026 guidance. The stock has been negatively impacted by fears surrounding FDA efforts to phase out animal testing and potential competition from AI. Analysts have offered various insights, with some raising price targets and others lowering them. The consensus rating for CRL stock is "hold."

Charles River Laboratories experiences demand seasonality, particularly in its Discovery and Safety Assessment (DSA) segment. Typical holiday seasonality in the fourth quarter and early January can affect near-term proposal and booking activity. Despite this, the company noted improving DSA net book-to-bill trends since the middle of fiscal 2025.

Charles River Laboratories International, Inc. (CRL) is an American pharmaceutical and biotechnology contract research organization (CRO) headquartered in Wilmington, Massachusetts. Founded in 1947, the company operates within the pharmaceuticals, biotechnology, gene therapy, cell therapy, medical devices, and contract research industries. CRL provides essential products and services to pharmaceutical and biotechnology companies, government agencies, and academic institutions globally, accelerating their research and drug development efforts. The company operates through three main segments: Research Models and Services (RMS) supplies research models and related services, Discovery and Safety Assessment (DSA) provides services for early drug development and safety assessment, and Manufacturing Solutions includes Microbial Solutions, Biologics Solutions, Avian Vaccine Services, and cell and gene therapy CDMO solutions.

Charles River Laboratories has a significant global presence, with operations spanning at least 20 countries and approximately 120 locations worldwide. The company has a strong footprint in North America, Europe, Asia, Australia, and Brazil.

In the past year, Charles River Laboratories has faced public scrutiny and regulatory attention concerning its use of laboratory animals. A notable event impacting its reputation involves criticism regarding its stance on recombinant Factor C (rFC), with critics arguing that CRL prioritizes its LAL supply over environmental concerns and the adoption of animal-free alternatives.

Charles River Laboratories International, Inc. (CRL) has a high concentration of institutional ownership. As of April 9, 2026, there were 585 institutional owners and shareholders holding a total of 53,025,599 shares. Major institutional shareholders include Vanguard Group Inc., BlackRock, Inc., and Invesco Ltd. Insider ownership, including CEO James C. Foster, is modest, typically a small single-digit percentage.